Michael Cecchini, MD
Hematology & Oncology · New Haven, CTNPI 1184999336
Payments from drug & device makers
Across 1,148 payments — averaging $6762.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1.8M
- Merck$1M
- Boehringer Ingelheim$732K
- Beigene, Ltd.$665K
- Mirati Therapeutics, Inc.$597K
- AstraZeneca$567K
- plus $2.4M from 28 others
Across 5 payments — averaging $1357.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$4K
- Macrogenics, Inc.$1K
- F. Hoffmann-la Roche AG$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 503 | $1,805,790 |
| Merck | 16 | $1,017,714 |
| Boehringer Ingelheim | 31 | $731,570 |
| Beigene, Ltd. | 27 | $664,889 |
| Mirati Therapeutics, Inc. | 17 | $596,503 |
| AstraZeneca | 17 | $567,404 |
| Beone Medicines USA, Inc. | 43 | $551,178 |
| Bayer | 37 | $401,895 |
| Genentech, Inc. | 87 | $390,932 |
| Beigene USA, Inc. | 109 | $284,763 |
| Ipsen Pharma SAS | 71 | $180,962 |
| Janssen Research & Development, LLC | 12 | $153,321 |
| Beone Medicines Ltd. | 6 | $111,037 |
| Daiichi Sankyo Inc. | 54 | $91,187 |
| Boehringer Ingelheim International GmbH | 29 | $47,243 |
| Eli Lilly | 5 | $40,917 |
| Sanofi US Services Inc. | 9 | $39,874 |
| EMD Serono, Inc. | 9 | $23,824 |
| Seagen Inc. | 9 | $12,843 |
| Taiho Oncology, Inc. | 5 | $10,208 |
| Incyte Corporation | 10 | $8,890 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 3 | $7,363 |
| Eisai Inc. | 10 | $5,850 |
| Regeneron | 9 | $4,974 |
| Agios Pharmaceuticals, Inc. | 6 | $3,792 |
| Astellas Pharma Global Development | 1 | $2,704 |
| Hoffmann-la Roche Limited | 1 | $2,170 |
| F. Hoffmann-la Roche AG | 5 | $1,888 |
| Exelixis Inc. | 1 | $1,650 |
| Astrazeneca AB | 1 | $135 |
| Janssen Scientific Affairs, LLC | 1 | $104 |
| Aroa Biosurgery Incorporated | 2 | $48 |
| Genentech USA, Inc. | 1 | $46 |
| Ardelyx, Inc. | 1 | $22 |
How this compares
$7,763,689 in reported general payments places this provider in the 95th percentile of 163 hematology & oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in New Haven
- Amer ZeidanNew Haven$15.5M
- Nataliya UbohaNew Haven$13.3M
- Tarsheen SethiNew Haven$2.6M
- Terri ParkerNew Haven$2.4M
- Iris IsufiNew Haven$2.1M
- Walid ShaibNew Haven$1.9M
- Melinda YushakNew Haven$1.7M
- Scott HuntingtonNew Haven$712K
- Shalin KothariNew Haven$421K
- Maximilian StahlNew Haven$240K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.